Find Locations
For hours, walk-ins and appointments.Synonyms
- HER-2 Extracellular Domain (ECD)
- HER-2/neu Shed Antigen
Expected Turnaround Time
5 days
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
Related Documents
Specimen Requirements
Specimen
Serum, frozen
Volume
1 mL
Minimum Volume
0.2 mL
Container
Red-top tube or gel-barrier tube
Collection
Transfer serum to screw-cap tube for shipping. Freeze specimen at -20°C and ship on dry ice. To avoid delays in turnaround time when requesting multiple tests on frozen samples, please submit separate frozen specimens for each test requested.
Storage Instructions
Freeze
Causes for Rejection
Hemolysis; defrosted or freeze-thawed specimen
Test Details
Use
This test is used for the quantitative measure of HER-2/neu in human serum. HER-2/neu values obtained may be used in the follow-up and monitoring of patients with metastatic breast cancer. HER-2/neu values should be used in conjunction with information available from clinical and other diagnostic procedures in the management of breast cancer. The clinical utility of the measurement of HER-2/neu as a prognostic indicator for early recurrence and in the management of patients on immunotherapy regimens has not been fully established.
Limitations
Elevated levels of serum HER-2/neu are observed in a subset of patients with HER-2/neu-positive tumors. Approximately 25% to 30% of breast cancers demonstrate overexpression of the HER-2/neu protein.
Methodology
Immunochemiluminometric (ICMA)
References
Fehm T, Maimonis P, Weitz S, Teramoto Y, Katalinic A, Jäger W. Influence of circulating c-erbB-2 serum protein on response to adjuvant chemotherapy in node-positive breast cancer patients. Breast Cancer Res Treat. 1997 Mar; 43(1):87-95. 9065602
Molina R, Jo J, Filella X, et al. C-erbB-2 oncoprotein in the sera and tissue of patients with breast cancer. Utility in prognosis. Anticancer Res. 1996 Jul-Aug; 16(4B):2295-2300.8694559
LOINC® Map
| Order Code | Order Code Name | Order Loinc | Result Code | Result Code Name | UofM | Result LOINC |
|---|---|---|---|---|---|---|
| 480136 | HER-2/neu, Serum | 480134 | Her-2/neu, Serum | ng/mL | 42914-2 | |
| 480136 | HER-2/neu, Serum | 511958 | 80563-0 |
© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.
CPT Statement/Profile Statement
The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf